Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing extranodal manifestations in nearly 50% of cases, particularly in the skin ...

Discover IMRX’s innovative cancer drug atebimetinib and upcoming milestones. Learn about trial results, financial outlook, ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

The discussion focuses on the unique treatment approach for BRAF V600E–mutant NSCLC, which differs from other oncogenic drivers such as EGFR or ALK that are typically treated with single-agent ...

HIGH POINT, N.C. — The American Home Furnishings Hall of Fame Foundation will celebrate those newly honored in the Pathways of Honor surrounding the Wanek Family and Ashley Furniture Industries ...

ABSTRACT: Increasing Antimicrobial Resistance (AMR) compromises the treatment of Helicobacter pylori infection globally. This study aimed to use probiotics together with an antibiotic regimen and a ...

NEW YORK – Recently released data from the investigator-initiated FRAME trial has lent further support to the activity of Verastem Oncology's RAF/MEK clamp and FAK inhibitor combination Avmapki ...

This slideshow highlights some of the latest breakthroughs in breast cancer treatment, spotlighting key molecular pathways—PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, JAK/STAT, and SRC—that are driving innovation ...